J&J suing Samsung Bioepis over Stelara biosimilar

J&J sues Samsung Bioepis over Stelara biosimilar
Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis treatment.
J&J Takes Samsung Bioepis to Court Over ‘Unlawful’ Stelara Biosimilar Sublicense
Samsung Bioepis allegedly entered into an agreement with a third-party health company, allowing it to market its own private label of a Stelara biosimilar.
Biosimilar Battle: J&J Sues Samsung Over Stelara Market Intrusion
Johnson & Johnson filed a lawsuit against Samsung Bioepis for allegedly breaching their agreement over the launch of Stelara's biosimilar, Pyzchiva. J&J seeks to prevent its U.S. sales, claiming unauthorized sublicense dealing damaged J&J's market share.
J&J seeks to stop Sam­sung Bioepis from li­cens­ing Ste­lara biosim­i­lar
Johnson & Johnson is suing Samsung Bioepis for allegedly breaching the terms of a contract regarding the launch of the Korean biotech’s Stelara biosimilar.
J&J sues Samsung Bioepis over ‘surreptitious’ breach of Stelara biosimilar contract
Samsung Bioepis has allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous settlement.
J&J sues Samsung Bioepis over contract breach for Stelara biosimilar
Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the drugmaker over the launch of a biosimilar to Stelara, J&J's autoimmune drug.
J&J sues Samsung over a contract breach for a Stelara biosimilar
As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one manufacturer of striking a
Samsung Bioepis Announces US Launch of PYZCHIVA(R) (ustekinumab-ttwe), Biosimilar to Stelara
Samsung Bioepis Co., Ltd. today announced that PYZCHIVA(R) (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), is now available in the United States. PYZCHIVA has been appr
centerforbiosimilars21h
3 Ustekinumab Biosimilars Launch on US Market
Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...
Teva Pharma and Alvotech launch biosimilar to J&J's Stelara in US
Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States, the second in a wave of near-copies of the ...